This clinical trial is focused on studying the effects of a new treatment for Systemic Lupus Erythematosus (SLE), a chronic autoimmune disease where the immune system attacks healthy tissues, causing inflammation and damage to various parts of the body. The treatment being tested is called BIIB059, also known as litifilimab, which is a type of protein called a recombinant monoclonal antibody. This study aims to evaluate how effective and safe BIIB059 is for adults with active SLE who are already receiving standard care for lupus.

Participants in the study will receive either the BIIB059 treatment or a placebo, which looks like the treatment but does not contain the active ingredient. The study will last for about a year, during which participants will have regular check-ups to monitor their health and the activity of their lupus. The goal is to see if BIIB059 can reduce the symptoms and activity of lupus more effectively than the placebo.

Throughout the study, various aspects of the participants’ health will be assessed, including their response to the treatment and any changes in their lupus symptoms. The study will also track any side effects or adverse events that may occur. This research is important for understanding whether BIIB059 can be a beneficial treatment option for people living with systemic lupus erythematosus.